Anticancer potential of isovanillin-based symmetrical azine: Synthesis, structure, molecular modeling, in silico leukemia inhibition and MD simulation

Isovanillin azine, a symmetrical azine easily synthesized by reaction of 3-hydroxy-4-methoxybenzaldehyde (isovanillin) with hydrazine hydrate, was identified as a potential inhibitor of the Human T-cell Leukemia Virus type 1 (HTLV-1) protease (2B7F). The compound was characterized using FT-IR, UV-VIS, H-1 NMR, and C-13 NMR spectroscopic techniques, as well as by single-crystal X-ray diffraction at 100 K. Additionally, calculations were conducted on the FMOs, particularly the HOMO-LUMO, to determine the forbidden energy gap and assess the compound's properties. To properly and accurately evaluate the effectiveness of our product as an anticancer drug, we investigated its interactions with 2B7F through molecular docking experiment and MD simulation. The results indicate that isovanillin azine has the potential to effectively inhibit 2B7F, laying the groundwork for the development of targeted treatments for HTLV-1-related disorders.